A phase II,single arm,open-label study to assess Maintenance Therapy of Chidamide in Patients With Hepatitis B Virus(HBV)Positive Diffuse Large B-cell Lymphoma with complete response after completion of prior chemotherapy
Objective to evaluate the efficacy and safety of maintenance therapy with Chidamide in patients With Hepatitis B Virus(HBV)Positive Diffuse Large B-cell Lymphoma(DLBCL) with complete response after completion of prior chemotherapy, so as to provide the basis for the application of Chidamide in HBV positive DLBCL
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Tucidinostat Specification: 5mg / tablet. Dosage: oral, 20 mg (3 tablets) each time, twice a week, with the interval of no less than 3 days (such as Monday and Thursday, Tuesday, Friday, Wednesday and Saturday, etc.)
The First Bethune Hospital of Jilin University
Changchun, Jilin, China
Progression-free survival
Progression-free survival(by IWC)
Time frame: 6months
Overall survival
Overall survival
Time frame: 12months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.